Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human papillomavirus associated cancers that have come back or spread to other places in the body. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and durvalumab may work better in treating patients with human papillomavirus associated cancers.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the anti-tumor activity of DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 (MEDI0457) in combination with durvalumab. SECONDARY OBJECTIVES: I. To determine the safety profile of MEDI0457 in combination with durvalumab in patients with recurrent/metastatic human papilloma virus (HPV) 16- or 18- associated cancer. II. To evaluate the progression-free survival (PFS) and overall survival (OS) of patients with recurrent/metastatic incurable HPV-16/18 positive solid malignancies receiving the combination of MEDI0457and durvalumab. III. To evaluate objective response rate (ORR) by immune-related criteria of the combination of MEDI0457 and durvalumab in patients with recurrent/metastatic incurable HPV-16/18 positive solid malignancies. IV. To evaluate the disease control rate at 24 weeks. EXPLORATORY OBJECTIVES: I. To determine the cellular and humoral immune response to immunotherapy with MEDI0457 in combination with durvalumab, II. To examine the correlation between anti tumor activity and biomarkers including: IIa. HPV-specific cellular and humoral responses. IIb. Programmed death ligand 1 status. IIc. The number of tumor infiltrating lymphocytes, HPV 16/18 E6/E7 deoxyribonucleic acid (DNA) levels and HPV 16/18 E6/E7 DNA sequence in biopsy tissue and plasma. III. To evaluate the pharmacokinetics and anti-drug antibodies (ADA) for durvalumab. OUTLINE: Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 intramuscularly (IM) and via electroporation at 1, 3, 7, and 12 weeks and durvalumab intravenously (IV) at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 90 days, every 3 months for 12 months, and then every 6 months thereafter. ;


Study Design


Related Conditions & MeSH terms

  • Anus Neoplasms
  • Carcinoma
  • Human Papillomavirus-16 Positive
  • Human Papillomavirus-18 Positive
  • Metastatic Malignant Neoplasm
  • Neoplasms
  • Penile Neoplasms
  • Recurrence
  • Recurrent Anal Canal Carcinoma
  • Recurrent Cervical Carcinoma
  • Recurrent Malignant Neoplasm
  • Recurrent Penile Carcinoma
  • Recurrent Vaginal Carcinoma
  • Recurrent Vulvar Carcinoma
  • Refractory Malignant Neoplasm
  • Stage IV Anal Cancer AJCC v8
  • Stage IV Cervical Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IV Vaginal Cancer AJCC v8
  • Stage IV Vulvar Cancer AJCC v8
  • Stage IVA Cervical Cancer AJCC v8
  • Stage IVA Vaginal Cancer AJCC v8
  • Stage IVA Vulvar Cancer AJCC v8
  • Stage IVB Cervical Cancer AJCC v8
  • Stage IVB Vaginal Cancer AJCC v8
  • Stage IVB Vulvar Cancer AJCC v8
  • Uterine Cervical Neoplasms
  • Vaginal Neoplasms
  • Vulvar Neoplasms

NCT number NCT03439085
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 14, 2018
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03968406 - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Phase 1
Active, not recruiting NCT03508570 - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Phase 1
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Recruiting NCT04574635 - Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Terminated NCT03345784 - Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Phase 1
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT05310331 - Donafenib for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310383 - Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Recruiting NCT05290935 - Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Phase 2
Recruiting NCT06238635 - Dostarlimab and Cobolimab in Advanced Cervical Cancer Phase 2
Completed NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT06157151 - PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Phase 2
Completed NCT00499031 - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00041093 - Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2